Harvest Fund Management Co. Ltd Boosts Stake in Glaukos Co. (NYSE:GKOS)

Harvest Fund Management Co. Ltd raised its position in Glaukos Co. (NYSE:GKOS) by 438.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,838 shares of the medical instruments supplier’s stock after purchasing an additional 3,940 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Glaukos were worth $726,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC increased its stake in Glaukos by 1.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after buying an additional 89 shares during the last quarter. HighTower Advisors LLC increased its stake in Glaukos by 2.8% in the 4th quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after buying an additional 91 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in Glaukos by 0.4% in the 4th quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock valued at $4,003,000 after buying an additional 100 shares during the last quarter. Handelsbanken Fonder AB increased its stake in Glaukos by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock valued at $2,204,000 after buying an additional 100 shares during the last quarter. Finally, KBC Group NV increased its stake in Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after buying an additional 201 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Down 0.4 %

Shares of NYSE:GKOS opened at $100.86 on Friday. The firm has a fifty day moving average price of $136.42 and a two-hundred day moving average price of $136.75. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a one year low of $86.74 and a one year high of $163.71. The company has a market cap of $5.71 billion, a price-to-earnings ratio of -35.14 and a beta of 0.99.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on GKOS shares. Wells Fargo & Company increased their target price on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and increased their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. BTIG Research increased their target price on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. UBS Group started coverage on shares of Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company. Finally, Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 target price for the company. in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $163.25.

Insider Buying and Selling at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 6.40% of the company’s stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.